Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2009-7-22
pubmed:abstractText
Angiotensin II plays a key role in the development of cardiac hypertrophy. The contribution of the angiotensin II type 1 receptor (AT1) in angiotensin II-induced cardiac hypertrophy is well established, but the role of AT2 signaling remains controversial. Previously, we have shown that natriuretic peptide receptor/guanylyl cyclase-A (GCA) signaling protects the heart from hypertrophy at least in part by inhibiting AT1-mediated pro-hypertrophic signaling. Here, we investigated the role of AT2 in cardiac hypertrophy observed in mice lacking GCA. Real-time RT-PCR and immunoblotting approaches indicated that the cardiac AT2 gene was overexpressed in GCA-deficient mice. Mice lacking AT2 alone did not exhibit an abnormal cardiac phenotype. In contrast, GCA-deficiency-induced increases in heart to body weight ratio, cardiomyocyte cross-sectional area, and collagen accumulation as evidenced by van Gieson staining were attenuated when AT2 was absent. Furthermore, the up-regulated cardiac expression of hypertrophy-related genes in GCA-null animals was also suppressed. Pharmacological blockade of AT2 with PD123319 similarly attenuated cardiac hypertrophy in GCA-deficient mice. In addition, whereas the AT1 antagonist olmesartan attenuated cardiac hypertrophy in GCA-deficient mice, this treatment was without effect on cardiac hypertrophy in GCA/AT2-double null mice, notwithstanding its potent antihypertensive effect in these animals. These results suggest that the interplay of AT2 and AT1 may be important in the development of cardiac hypertrophy. Collectively, our findings support the assertion that GCA inhibits AT2-mediated pro-hypertrophic signaling in heart and offer new insights into endogenous cardioprotective mechanisms during disease pathogenesis.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin II Type 2 Receptor..., http://linkedlifedata.com/resource/pubmed/chemical/Collagen, http://linkedlifedata.com/resource/pubmed/chemical/Imidazoles, http://linkedlifedata.com/resource/pubmed/chemical/PD 123319, http://linkedlifedata.com/resource/pubmed/chemical/Pyridines, http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Angiotensin, Type 1, http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Angiotensin, Type 2, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Atrial Natriuretic Factor, http://linkedlifedata.com/resource/pubmed/chemical/Tetrazoles, http://linkedlifedata.com/resource/pubmed/chemical/Vasoconstrictor Agents, http://linkedlifedata.com/resource/pubmed/chemical/atrial natriuretic factor receptor A, http://linkedlifedata.com/resource/pubmed/chemical/olmesartan
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1945-7170
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
150
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3759-65
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:19372206-Angiotensin II Type 2 Receptor Blockers, pubmed-meshheading:19372206-Animals, pubmed-meshheading:19372206-Body Weight, pubmed-meshheading:19372206-Cardiomegaly, pubmed-meshheading:19372206-Collagen, pubmed-meshheading:19372206-Heart, pubmed-meshheading:19372206-Imidazoles, pubmed-meshheading:19372206-Immunoblotting, pubmed-meshheading:19372206-Male, pubmed-meshheading:19372206-Mice, pubmed-meshheading:19372206-Mice, Knockout, pubmed-meshheading:19372206-Myocardium, pubmed-meshheading:19372206-Organ Size, pubmed-meshheading:19372206-Pyridines, pubmed-meshheading:19372206-Receptor, Angiotensin, Type 1, pubmed-meshheading:19372206-Receptor, Angiotensin, Type 2, pubmed-meshheading:19372206-Receptors, Atrial Natriuretic Factor, pubmed-meshheading:19372206-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:19372206-Tetrazoles, pubmed-meshheading:19372206-Vasoconstrictor Agents
pubmed:year
2009
pubmed:articleTitle
Guanylyl cyclase-A inhibits angiotensin II type 2 receptor-mediated pro-hypertrophic signaling in the heart.
pubmed:affiliation
Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan. yuhao@kuhp.kyoto-u.ac.jp
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't